Serum p53 antibody in breast cancer

被引：5

作者：

Yamamoto, Shinya ^{[1
]}

Chishima, Takashi ^{[1
]}

Adachi, Shouko ^{[1
]}

Harada, Fumi ^{[1
]}

Toda, Youko ^{[1
]}

Arioka, Hitoshi ^{[1
]}

Hasegawa, Naoki ^{[1
]}

Kakuta, Yukio ^{[1
]}

机构：

[1] Yokohama Rousai Hosp, Dept Breast Canc, Kouhoku Ku, Yokohama, Kanagawa 2220036, Japan

来源：

CANCER BIOMARKERS | 2014年 / 14卷 / 04期

关键词：

p53; breast cancer; NETWORK; TUMORS;

D O I：

10.3233/CBM-140396

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: The significance of the measurement of anti-p53 antibodies in serum remains undisclosed. The aim of this study was to assess anti-p53 antibodies in the serum of patients with breast cancer, and correlate these results with various clinicopathologic parameters. METHODS: We analyzed serum anti-p53 antibody levels in 124 patients with breast cancers and 7 patients with benign disease between April 2012 and March 2013, as well as levels of serum carcinoembryonic antigen (CEA) and cancer antigen (CA) 15-3. RESULTS: Twenty-two of 124 patients with breast cancer had an increased concentration of anti-p53 antibodies. By distribution of clinical stage, in stage 0-II the positive ratio of anti-p53 antibodies was significantly higher than that of CEA (p = 0.03) and CA15-3 (p = 0.01). There was a significant correlation between anti-p53 antibodies and family history (p = 0.03). Triple-negative cancer also showed a significant correlation with anti-p53 antibodies (p = 0.007). In patients with multiple and/or bilateral breast cancer, the level of anti-p53 was significantly higher than in unilateral breast cancer (62.5% vs 14.7%, p = 0.004). CONCLUSION: Measurement of anti-p53 antibodies is useful for the prevention of oversight in the evaluation of multiple and/or bilateral breast cancer.

引用

页码：203 / 206

页数：4

共 21 条

[1] The p53 network [J].

Agarwal, ML ;

Taylor, WR ;

Chernov, MV ;

Chernova, OB ;

Stark, GR .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (01) :1-4

[2] Tumor suppressor p53 is required to modulate BRCA1 expression [J].

Arizti, P ;

Fang, L ;

Park, I ;

Yin, YX ;

Solomon, E ;

Ouchi, T ;

Aaronson, SA ;

Lee, SW .

MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (20) :7450-7459

[3] TP53 and breast cancer [J].

Borresen-Dale, AL .

HUMAN MUTATION, 2003, 21 (03) :292-300

[4] DETECTION OF ANTIBODIES AGAINST THE CELLULAR PROTEIN P53 IN SERA FROM PATIENTS WITH BREAST-CANCER [J].

CRAWFORD, LV ;

PIM, DC ;

BULBROOK, RD .

INTERNATIONAL JOURNAL OF CANCER, 1982, 30 (04) :403-408

[5] p53 involvement in BRCA1-associated breast cancer [J].

Eisinger, F ;

Jacquemier, J ;

Guinebretiere, JM ;

Birnbaum, D ;

Sobol, H .

LANCET, 1997, 350 (9084) :1101-1101

[6]

HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551

[7]

Koji H, 2006, J JPN SURG ASS, V67, P1498

[8] Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients [J].

Kulic, A. ;

Sirotkovic-Skerlev, M. ;

Jelisavac-Cosic, S. ;

Herceg, D. ;

Kovac, Z. ;

Vrbanec, D. .

MEDICAL ONCOLOGY, 2010, 27 (03) :887-893

[9] P53 STATUS AND THE EFFICACY OF CANCER-THERAPY IN-VIVO [J].

LOWE, SW ;

BODIS, S ;

MCCLATCHEY, A ;

REMINGTON, L ;

RULEY, HE ;

FISHER, DE ;

HOUSMAN, DE ;

JACKS, T .

SCIENCE, 1994, 266 (5186) :807-810

[10] Serum appearance of anti-p53 antibody in triple negative breast cancer [J].

Nozoe, Tadahiro ;

Mori, Emiko ;

Kono, Mayuko ;

Iguchi, Tomohiro ;

Maeda, Takashi ;

Matsukuma, Akito ;

Ezaki, Takahiro .

BREAST CANCER, 2012, 19 (01) :11-15

← 1 2 3 →